The FDA accelerated review for three psychedelic programs by issuing national priority commissioner’s vouchers under a Trump administration push to expand access to mental health treatments. Vouchers were tied to Compass Pathways’ psilocybin product for treatment-resistant depression, the Usona Institute’s MDMA-like therapy concept for major depressive disorder, and Transcend Therapeutics’ MDMA-like program for post-traumatic stress disorder. Separately, reporting indicated that the FDA’s selections were not limited to sponsorship transparency in advance of public disclosure, though Compass confirmed receipt of a voucher. The move adds regulatory momentum to psychedelic drug development and can materially affect timelines and commercial strategy through the potential to leverage review vouchers.